Jogeshwari, India

Time filter

Source Type

News Article | May 17, 2017
Site: www.prnewswire.com

The seven categories for 2017 are: Law Enforcement/Arson Dogs, sponsored by the K-9 Courage Program™ from Zoetis; Military Dogs, sponsored by the K-9 Courage Program from Zoetis; Therapy Dogs, sponsored by Chicken Soup for the Soul Pet Food, the official pet food of the 2017 Hero Dog Awards; Service Dogs, sponsored by Modern Dog magazine; Emerging Hero Dogs, a category that pays tribute to ordinary dogs who do extraordinary things, sponsored by Boehringer Ingelheim Animal Health, maker of NexGard® (afoxolaner) Chewables; Search and Rescue Dogs; and Guide/Hearing Dogs. Over the past six years, Americans have cast millions of votes for more than a thousand dogs, all seeking the coveted title of American Hero Dog. The program reaches more than one billion people each year and draws the support and participation of top celebrity dog lovers from all over the world. Hosts, judges, award presenters, and entertainment acts have included Katharine McPhee, Alison Sweeney, Bindi Irwin, Derek Hough, Michelle Beadle, Victoria Stilwell, Betty White, Whoopi Goldberg, Denise Richards, Gary Sinise, Burt Reynolds, Chelsea Handler, Martin Short, Jewel, Wilson Phillips, John Ondrasik, Carson Kressley, Miranda Lambert, Pauley Perrette, Kristen Chenoweth, Naomi Judd, Lori Loughlin, Lea Thompson, Eric Stonestreet, Fred Willard, Danica McKellar, Bailee Madison, and many, many more. "For thousands of years, mankind has had a special relationship with dogs, and the American Humane Hero Dog Awards are our way of honoring the best of our best friends," said Dr. Robin Ganzert, American Humane president and CEO. "This unique awards show celebrates the unbreakable human-animal bond, which has been a core part of our organization's mission since 1877." "The Hero Dog Awards recognize some of America's bravest heroes on both ends of the leash," said philanthropist and presenting sponsor Lois Pope. "From those who defend our country to those who help us heal, guide us, protect us, and help find the lost, every single contender exemplifies the courage and heroism we seek to spotlight in this campaign. Our goal is not only to honor these magnificent dogs but to inspire America to reflect on the outsized contributions that animals make in our lives each and every day." Here are brief descriptions, written by the hero dogs' owners/handlers: For more information about the 2017 American Humane Hero Dog Awards®, and to vote daily in the contest, please visit www.herodogawards.org. For more information on sponsorship opportunities email Mari Harner at marih@americanhumane.org  or call 1-800-227-4645. American Humane is the country's first national humane organization, founded in 1877. For more information, please visit www.americanhumane.org. To inquire about Hero Dog Awards sponsorship opportunities, please email Mari Harner at marih@americanhumane.org. About Lois Pope, The Lois Pope LIFE Foundation, Inc., and LIFE (Leaders in Furthering Education) As one of America's leading philanthropists, Lois Pope has positively impacted the lives of individuals at the local, national and international levels.  She has established three separate organizations dedicated to helping those in need.  These organizations are the Lois Pope LIFE Foundation, Inc., Leaders In Furthering Education (LIFE), and the Disabled Veterans' Life Memorial Foundation.  For more than 20 years she has been the driving force behind the Lois Pope LIFE Center at the University of Miami School of Medicine, The American Veterans Disabled for Life Memorial, and a groundbreaking new program with American Humane in Palm Beach County. Lois Pope has recently donated two Lois Pope Red Star Rescue Vehicles. Each rescue vehicle is a 50-foot long response unit, complete with a Ford F-350 truck and trailer, which is specifically designed and outfitted to provide an array of animal emergency services and cruelty responses within the region. Mrs. Pope recently saw the completion of a decade's long dream – the American Veterans Disabled for Life Memorial, which was dedicated by President Obama in Washington, DC on Sunday, October 5, 2014. The Memorial will forever stand as a reminder to the public and legislators of the courage and sacrifices of the four million living disabled veterans and all those who died before them for the need to be vigilant in assuring their support, as well as being aware of the human cost of war. A mother and a grandmother, Lois has trained for and completed five New York City Marathons. Hallmark Channel is Crown Media Family Networks' flagship 24-hour cable television network, distributed nationwide in high definition (HD) and standard definition (SD) to 89 million homes.  As the country's leading destination for quality family entertainment, Hallmark Channel delivers on the 100-year legacy of the Hallmark brand.  In addition to its signature new, original movies, the network features an ambitious lineup of other new, original content, including scripted primetime series, such as "Good Witch," "When Calls the Heart" and "Chesapeake Shores"; annual specials including "Kitten Bowl" and "Hero Dog Awards"; and a daily, two-hour lifestyle show, "Home & Family."  Additionally, Hallmark Channel is the exclusive home to world premiere presentations of the acclaimed Hallmark Hall of Fame franchise.  Dedicated to helping viewers celebrate life's special moments, Hallmark Channel also offers annual holiday programming franchises, including "Countdown to Christmas," "Countdown to Valentine's Day," "Summer Nights," "Fall Harvest" and "Winterfest."  Rounding out the network's diverse slate are some of television's most beloved comedies and series, including "The Golden Girls," "The Middle," "Last Man Standing," and "Frasier." For more information, please visit www.crownmediapress.com  Hallmark Channel on Social Media: Facebook, Twitter, Pinterest, YouTube Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here. Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry's top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com. About Chicken Soup for the Soul Pet Food Chicken Soup for the Soul understands the unique relationship between people and pets. Health conscious consumers have been feeding their cats and dogs Chicken Soup for the Soul wholesome and balanced, super premium pet food for over a decade. Holistic in nature, the entire line of products is made from only the finest ingredients: real meats (chicken, turkey, duck and salmon), fruits, vegetables and herbs. With no added corn, wheat, soy, artificial coloring, flavoring or preservatives, Chicken Soup for the Soul pet food is inspired by your love for pets, and promotes overall health and well-being for dogs and cats.  The products are proudly made in the USA, and feature rescued shelter pets on every bag. Core and grain-free formulas are available in independent pet specialty stores nationwide and online, with a new line of treats recently launched. A portion of all proceeds from the sale of Chicken Soup for the Soul pet food goes to help shelters and pets in need through Chicken Soup for the Soul's Fill a Bowl … Feed a Soul™ program. The program which was launched in association with the American Humane aims to provide a million meals to shelter pets in 2017. www.chickensouppets.com Modern Dog -- "the best dog magazine ever" and the #1 dog publication in North America -- is a must-read for dog lovers. Your source for the best ideas and solutions for life with dogs, Modern Dog features training tips, insight into your dog's behavior, the best gear, wellness, rescue, DIY how-tos, contests and more! A large part of Modern Dog's mission is to support rescue and the organizations that work tirelessly to help dogs in need. Find Modern Dog online -- www.moderndogmagazine.com -- on newsstands across North America, and on all major social platforms. Modern Dog, your guide to a better bond with your dog! To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/21-remarkable-canines-competing-to-become-americas-top-dog-300459579.html


News Article | May 26, 2017
Site: www.prnewswire.com

"Our 181 nominated Hero Veterinarians and Hero Veterinary Technicians are outstanding examples of the veterinary community," said J. Michael McFarland, DVM, DABVP, group director, Companion Animal Marketing at Zoetis. "The American Humane Hero Veterinarian and Veterinary Technician Awards are Zoetis' way of giving back to those who keep our best friends healthy and strengthen the life-enhancing, even life-saving human-animal bond. Congratulations to our 10 extraordinary finalists!" "Veterinarians and veterinary technicians are heroes to our animals, and to us," said Dr. Robin Ganzert, president and CEO of American Humane. "These dedicated professionals work behind the scenes and without fanfare to keep these family members happy and healthy. We and the nation want to thank them, one and all!" To read each of the nominees' stories, as told by the people who nominated them, and to vote daily for one of the five finalists in each of the American Hero Veterinarian and American Hero Veterinary Technician categories, please visit www.herovetawards.org. Here are the nomination essays written by their supporters: Dr. Nicole McArthur (Granite Bay, CA) Veterinarians are at a risk for suicide several times greater than the national average and in 2014 the tragic death by her own hand of Dr. Sophia Yin shocked the profession. This was the catalyst for Dr. McArthur, having dealt with depression and burn out herself, to start a peer-to-peer veterinary mental health support group. Initially it was just a few veterinarian Facebook friends. Then other veterinarians learned of it and wanted to join. And still more joined, until it went both viral and global. As of this writing more than 11,000 veterinarians are part of the Not One More Vet family. Lives have been changed and saved because many veterinarians have found they now have a safe place to turn to talk about their problems and receive loving, non-judgmental support. Not One More Vet is now Not One More Vet, Inc. and not-for-profit status is pending. The corporation will raise money for mental health education to help fulfill Dr. McArthur's initial goal: that not one more vet would see suicide as an alternative. Dr. McArthur is my hero veterinarian because she saw a need and addressed it. What's more, her vision touches thousands of veterinarians, who in turn touch thousands of clients and patients and better their lives. That's a true hero. Dr. Patricia Canchola (Pueblo, CO) Dr. Patti, as she is known in our community, has worked as a shelter veterinarian for Pueblo Animal Services since 2009. She is the only veterinarian on staff and performs between 3,500 and 4,500 spay and neuter surgeries every year. In addition, she performs about 200 other surgeries, treating animals that have trauma-related injuries, masses, broken bones and other injuries. She is responsible for the care of approximately 5,000 animals at the shelter every year, and cares for all with compassion, sensitivity and professionalism. Last year, Dr. Patti took it upon herself to take veterinary forensics courses to be better trained when examining abused, neglected and mistreated animals that are part of criminal investigations. She regularly testifies in animal cruelty criminal trials, being the voice for the animal victims, so that they may be heard. On top of this very busy and difficult job, she operates her own non-profit pet food bank, helping hundreds of families every year to feed their pets. As if that was not enough for her to do, she also runs an independent, low-cost pet health clinic two Saturdays a month, offering affordable vaccines, preventative health care and treatment of common illnesses and minor injuries. The Pueblo community experiences high levels of poverty, which absolutely affects pets every day. Low-income pet owners are able to better care for their pets thanks to her Amazin' Amos Pet Food Pantry and her St. Martin's Well Pet Clinic. David Crouch (Ashevile, NC) Dr. Crouch is an amazing man and veterinarian! I rescued a dog, Blue, from a cruelty case who needed special orthopedic surgery. I reached out to Dr. Crouch, who agreed to perform the surgery. While many miles and states separated us, his love for animals and desire to provide the best care proved that miles do not matter. Dr. Crouch, at his own expense, flew to us, picked up the broken baby and returned him to us on the road to healing. Aside from the giving of his time and money to retrieve and return Blue, Dr. Crouch discounted the surgery greatly, more than one can imagine. It doesn't stop there! Dr. Crouch is also a volunteer pilot with Pilots N Paws. He provides his service of flying homeless animals from state to state to begin a new life at no charge. The animals he flies to new homes are destined for euthanasia. When transports are problematic logistically, Dr. Crouch steps up! And if that isn't enough, he guided a personal friend to a surgeon who saved her dog from what was a death sentence. If Dr. Crouch can't save them, he finds those that can. His work is paramount in not only saving broken bodies, but saving lives as well. Dr. Crouch is a true hero! Dr. Karter Neal (Tucson, AZ) Dr. Neal was born and raised in Tucson. She received her undergraduate degree from University of Arizona, and in 2000, she received her DVM from Colorado State University. Dr. Neal's experience is in equine medicine, general practice, and shelter medicine. She is truly an inspiration and has been recognized by the Tucson Hispanic Chamber of Commerce as one of the 40 under 40. She has also been recognized for her service to many other veterinary organizations during her career. After working for the Humane Society of Southern Arizona for seven years, Dr. Neal purchased Santa Cruz Vet Clinic in 2013. In 2014, she formed Asavet Charities, a non-profit 501(c)(3) organization that offers subsidized care to pet owners in need at her clinic and in under-served areas of the Southwest, including several Native American Reservations. A recent donation has allowed the purchase of a mobile clinic by Asavet Charities in 2016. The mobile unit is now actively performing clinics across the Southwest. Dr. Neal's passion involves offering spay and neuter services and promoting access to basic wellness care for pets. She estimates that she has performed approximately 50,000 spay and neuter surgeries to date for dogs and cats as well as pigs, rabbits, horses and others. She volunteers at high-volume spay and neuter clinics on the Navajo Reservation and at the Hopkins Belize Humane Society. Dr. Neal, her husband, and two children share their home with eight shelter cats and two shelter dogs. Dr. Heather Wilson-Robles (College Station, TX) Dr. Heather Wilson-Robles is a "rock star" because she is an amazing teacher, clinician, oncologist and researcher as associate professor of oncology and Palmer Chair at Texas A&M University. As a cutting-edge oncologist who cares for animals with cancer, Heather has grit, an innovative spirit, compassion, and impact on cancer research for the betterment of both animals and people. Heather started in the Veterinary Small Animal Clinical Sciences Department in 2007 with her husband JC and a dream to develop new ways to treat pets with cancer. Almost immediately, she formed collaborations with scientists at MD Anderson Cancer Center to develop T-cell transplantation strategies for dogs with cancer. She has also investigated the interplay between tumor progression and treatment. While all of this work has significant impact, Heather is also devoted to the care of veterinary cancer patients. She understands how to discuss treatment and the emotional struggle that ensues towards the end of life. Much of her skills and compassion comes from her own family experience and personal journey. In 2014, Heather's husband, JC, was diagnosed with colon cancer, and Heather cared for him and supported him until he passed away April 2015. If we can cure cancer in dogs, we can cure cancer in people. Through Heather's strength, determination and grace, she is working even harder to find a cure through leadership of clinical trials, oncology research and mentoring of students. Jeni Hudson (Decatur, IL) Jeni is a CVT. She is great at her job. I always tell people Jeni has nerves of steel and healing hands. Jeni founded a rescue five years ago that takes in pups with cleft palates and other disabilities. She NEVER turns a pup away. Once she arranged a transport from New Mexico to Illinois to help save a pup with a cleft palate/hydrocephalus. She called him Pip. When he passed away, I thought she might stop rescuing all together; but she knew there were more who needed her. Jeni is always researching ways to help the pups receive the best outcome possible. She knows she cannot save them all; however, if they are willing to live she will fight to give them a chance. Jeni has cared for over 100 puppies in her career. She has spent hours tube-feeding pups who would otherwise die if not for her. She has helped the ones who were suffering to cross over even if it breaks her heart. She spares no expense to make sure they have the best of everything they need. Jeni is always advocating for the special needs pups, spreading awareness that they can survive if given a chance. She is changing the way medical professionals view these pups. Until Jeni worked at NGPC, pets with clefts were euthanized. Jeni was at a C-Section when a pup was born with a cleft palate. He was to be euthanized. Jeni knew he deserved a CHANCE at life. She offered to take the pup even after EVERYONE told her he would die. Funny how one puppy and one CVT could change the minds of so many. Suzanne Nunes (Moorpark, CA) Suzanne Nunes, RVT is the embodiment of compassion and patient advocacy. Suzanne is an exceptional technician with an emphasis in behavioral studies who constantly puts patient safety and well-being at the forefront of her job tasks. When she is not working in the hospital, she dedicates her spare time to volunteerism and canine rescue. In conjunction with Spark of Santa Barbara, Suzanne regularly helps to rescue dogs from a few Los Angeles county shelters with immense challenges and a kill rate of 80 percent. She has fostered several dogs for whom she has personally taken financial responsibility. She goes above and beyond for her foster pets including caring for their extensive surgical needs. You can also find Suzanne volunteering each week at Ventura County Animal Services (VCAS). She helps our local shelter community thrive by assisting in a Canine Confidence Program designed to mentally and physically stimulate dogs while building their overall confidence. Suzanne is not just a hero for pets, she is an incredible advocate for the welfare of other veterinary professionals and individuals in care-giving fields that are no stranger to depression and suicide. Suzanne is no stranger to immense personal loss. She utilizes her awe-inspiring strength, compassion, love, and experience to revitalize and unite those around her. Without a doubt, she is our American Hero Veterinary Technician and we think anyone who gets to know her would think so, too. Robin Post (Albany, CA) I first met Robin Post in 2008. She was a volunteer assistant on a Rural Area Veterinary Services field clinic in Covelo, CA. She was earnest, engaged and afraid she wasn't going to be able to handle our needs. Fast forward to 2017: Robin is a masterful RVT and exceptionally proficient and forward-thinking mentor. While her technical skills and knowledge base are truly exceptional, it is her commitment to the forgotten animals in our world that truly sets her apart as an inspiring Hero Veterinary Technician. Robin proactively seeks professional opportunities to help animals where others will not. She has worked in exceptionally emotionally and physically challenging situations to bring care to animals in extreme poverty, hoarding cases, and wildfires, as well as those on native nation reservations. She has been brave and has initiated programs that save lives where others have not. She developed a student veterinary technician training program in HQHVSN so that Stockton Animal Services could develop an ambitious spay-neuter program. As a result, the Live Release rate increased from 32 percent in 2012 to 83 percent in 2016, translating into an extra 6,000 lives saved each year. Robin's current professional magic is developing a community cat program for an expanded area of the East Bay. She is a quiet force who goes about her work without fanfare. Her life's calling to enhance the human-animal bond and help animals in need is palpable. Her efforts are pure. Robin Post is your 2017 hero. Taylor Short (Chesapeake, VA) One example that comes to mind is when she was caring for a retired Old Guard horse that was now in a veteran equestrian program. She spent the nights sleeping in the barn and all day caring for the horse. Even when veterinarians were conceding, she refused to give up on this American hero. After a couple weeks of care and sleepless nights, the horse was strong enough and went back to work as a veteran therapeutic horse. She has stepped away from her own life and gone to Pacific islands as well as South America. There she spent months teaching basic veterinarian skills to the locals to help care for their animals, as well as performing surgeries in the field to save animals' lives. Each time she takes more suitcases with treats and toys to share with the local kids and their animals than she does with her own belongings. While working in a local animal ER close to the military base, she is frequently requested by name when a service member brings in a working dog. She is known for going above and beyond to make sure the patient is given the best possible care and shown respect. She constantly shows her compassion for the animals. And now, she has two additional dogs in the family to show for it. The first is a paralyzed dachshund who she took home. After amazing rehabilitation, she is running and playing as she should. The other is a bulldog that was terminal and stopped eating. She now, too, is full of life and is healthy. Jessica Smith (Grand Prairie, TX) Jessica is a highly trained and dedicated individual and is essential to our animal shelter. Previously coming in from a private practice, Jessica had to overcome some obstacles and adjust to a slight learning curve with shelter medicine. She has done an amazing job learning and growing in this position and is our very own here when it comes to helping to keep our animals healthy in a shelter environment! Under the supervision of our licensed veterinarian, Jessica monitors and cares for 100-200 animals every day and has been the backbone of maintaining protocols that have helped us to treat and care for animals that previously would have had to have been euthanized. That is a lot of responsibility and pressure, and she has done it superbly since she came to our shelter as our Lead Technician (our only full-time technician!). She not only supports our veterinarian in diagnosing disease, making accurate prognoses, prescribing medications, and performing surgeries, she has had to maintain other duties, such as keeping inventories, developing SOPs, and working on "herd management" for our shelter among other nonveterinary related tasks. Jessica is great to work with and truly has been a hero to our animals here in Grand Prairie. We could not be more proud to have her on our team. American Humane is the country's first national humane organization, founded in 1877. For more information, please visit www.americanhumane.org. Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. Hallmark Channel is Crown Media Family Networks' flagship 24-hour cable television network, distributed nationwide in high definition (HD) and standard definition (SD) to 89 million homes.  As the country's leading destination for quality family entertainment, Hallmark Channel delivers on the 100-year legacy of the Hallmark brand.  In addition to its signature new, original movies, the network features an ambitious lineup of other new, original content, including scripted primetime series, such as "Good Witch," "When Calls the Heart" and "Chesapeake Shores"; annual specials including "Kitten Bowl" and "Hero Dog Awards"; and a daily, two-hour lifestyle show, "Home & Family."  Additionally, Hallmark Channel is the exclusive home to world premiere presentations of the acclaimed Hallmark Hall of Fame franchise.  Dedicated to helping viewers celebrate life's special moments, Hallmark Channel also offers annual holiday programming franchises, including "Countdown to Christmas," "Countdown to Valentine's Day," "Summer Nights," "Fall Harvest" and "Winterfest."  Rounding out the network's diverse slate are some of television's most beloved comedies and series, including "The Golden Girls," "The Middle," "Last Man Standing," and "Frasier." For more information, please visit www.crownmediapress.com  Hallmark Channel on Social Media: Facebook, Twitter, Pinterest, YouTube To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/meet-americas-top-10-veterinary-professionals-and-vote-for-your-favorites-300464596.html


News Article | May 25, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2017 Dental and Veterinary Conference on Wednesday, May 31, 2017, in New York, N.Y. Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. She is scheduled to present at 3:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.


ZAVENTEM, Bélgica--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) ha anunciado que la Comisión Europea ha concedido a la empresa una autorización para la comercialización de Cytopoint (lokivetmab), el primer tratamiento de anticuerpo monoclonal (mAb en sus siglas en inglés) aprobado en la Unión Europea para uso veterinario. Cytopoint está indicado para el tratamiento de los síntomas clínicos, incluidos los picores y la inflamación, asociados con la dermatitis atópica en perros de cualquier edad con un


ZAVENTEM, Belgio--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) oggi ha annunciato di avere ottenuto dalla Commissione Europea l’autorizzazione a commercializzare Cytopoint (lokivetmab), il primo anticorpo monoclonale (mAb) approvato per l’uso terapeutico nella pratica clinica veterinaria nell’Unione Europea. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare


ZAVENTEM, België--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) heeft vandaag bekendgemaakt dat de Europese Commissie het bedrijf een vergunning heeft gegeven voor het in handel brengen van Cytopoint (lokivetmab), de eerste in de EU goedgekeurde behandeling met een monoklonale antistof voor diergeneeskunde. Cytopoint is goedgekeurd voor de behandeling van de klinische symptomen verband houden met atopische dermatitis, zoals jeuk en ontstekingsreacties, bij honden van alle leeftijden die zwaarder zijn dan drie kilo. Cytopoint bestrijdt en neutraliseert canine interleukin-31 (cIL-31), een belangrijk eiwit dat jeuk veroorzaakt bij honden. Het medicijn wordt via injectie toegediend en zorgt voor snelle en langdurige verlossing van jeuk – het belangrijkste kenmerk van de allergische huidaandoening bij honden – en de ontstekingen en wonden die de ziekte veroorzaakt. Cytopoint draagt op de lange termijn bij aan een gezonder en beter leven voor honden die aan atopische dermatitis lijden en verlicht de frustraties en zorgen van hun baasjes. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.


News Article | May 5, 2017
Site: www.businesswire.com

ATLANTA--(BUSINESS WIRE)--Visioneering Technologies, Inc. (ASX: VTI), a US-based medical device company (‘Visioneering’ or ‘The Company’) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® Multifocal 1 Day Contact Lenses, is pleased to announce the recent expansion of its US sales force. In line with Visioneering’s plan to broaden and accelerate its US launch of NaturalVue Multifocal Contact Lenses, they have appointed Mr. Joshua Suarez as new District Sales Manager for the western United States and added 10 new sales representatives across the country. Mr. Suarez has over 14 years’ experience in senior sales roles in the healthcare and medtech industries in the US. Most recently, Joshua was the Regional Business Manager at Voyce (i4C Innovations Inc.) where he built a new region and led sales and training for the start-up remote monitoring device company. Prior to this, he was the Senior Area Business Manager at Zoetis Inc. Visioneering’s Senior Vice President of Sales & Marketing, Tony Sommer stated he was delighted with the seniority and depth of experience their new hires bring to VTI. “I am confident that Joshua’s leadership skills and extensive experience will enrich VTI as we focus on building strong and long term partnerships with the eye-care industry.” Mr. Sommer continued, “There is significant interest building around the NaturalVue Multifocal. Our recent successful finance raise is enabling us to increase our sales coverage and strengthen our commercialization efforts across the country.” These new, highly-experienced sales representatives will cover Northern and Southern California (Los Angeles, San Diego, Sacramento and San Francisco), the northeast (including New York City, Long Island, upstate New York, Connecticut and New Jersey), Ohio (Cincinnati) and the Carolinas. CEO and Executive Director Dr. Stephen Snowdy said, “We plan to build out our US sales force to 45 sales representatives over the next 12 months, and we are off to a sprinting start with the addition of 11 new sales personnel.” Visioneering Technologies, Inc. (VTI), headquartered in northern Atlanta, Georgia, is an innovative company dedicated to developing products that improve vision. With a portfolio of technologies, the company uses creative and differentiated design approaches to develop products that enhance practitioner and patient experiences. VTI optical designs have been awarded nine patents worldwide, with an additional ten pending. Strength in science, an entrepreneurial culture, and the ability to bring technology to life make Visioneering Technologies, Inc. a company to watch. For more information, visit www.vtivision.com/ or call 844-884-5367, ext. 104.


News Article | May 4, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2017 and reaffirmed its guidance for full year 2017. The company reported revenue of $1.2 billion for the first quarter of 2017, an increase of 6% compared with the first quarter of 2016. Net income for the first quarter of 2017 was $238 million, or $0.48 per diluted share, an increase of 17% on a reported basis. Adjusted net income1 for the first quarter of 2017 was $261 million, or $0.53 per diluted share, an increase of 9% and 10%, respectively, on a reported basis. Adjusted net income for the first quarter of 2017 excludes the net impact of $23 million for purchase accounting adjustments, acquisition-related costs and certain significant items. On an operational2 basis, revenue for the first quarter of 2017 increased 6%, excluding the impact of foreign currency. Adjusted net income for the first quarter of 2017 increased 10% operationally, excluding the impact of foreign currency. “In the first quarter of 2017, we continue to see positive results from our diverse portfolio, innovative new companion animal products, and a more efficient cost structure,” said Juan Ramón Alaix, Chief Executive Officer at Zoetis. “Our revenue grew 6% operationally in the first quarter, driven largely by sales of companion animal products such as Simparica, Apoquel and Cytopoint, and our livestock portfolio featured growth in swine, cattle and fish across our international markets. We posted 10% operational growth in adjusted net income – once again faster than revenue growth – as we continue delivering steady profitable results.” “As costs for our one-time initiatives are largely complete, we were able to deliver 17% growth in reported EPS and continue to focus our investments on the ongoing business,” said Glenn David, Executive Vice President and Chief Financial Officer at Zoetis. “We see a good runway for continued growth, based on our diverse portfolio and recently launched products, and we are reaffirming our full-year 2017 guidance.” Zoetis organizes and manages its commercial operations across two regional segments: the United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local trends and customer needs. In the first quarter of 2017: Zoetis continues to drive demand and strengthen its diverse portfolio through the introduction of new products, lifecycle innovations, business development initiatives, strong customer relationships and entry into new markets and technologies. In the first quarter of 2017: Zoetis reaffirmed its guidance for the full year 2017, which includes: Additional guidance on other items such as expenses and tax rate is included in the financial tables and will be discussed on the company's conference call this morning. Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review first quarter 2017 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on May 4, 2017. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. 1 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items. 2 Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis. Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com. Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us. See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). The guidance reflects foreign exchange rates as of late April 2017. Reconciliations of 2017 reported guidance to 2017 adjusted guidance follows: Certain amounts and percentages may reflect rounding adjustments.


News Article | April 27, 2017
Site: www.businesswire.com

ZAVENTEM, Belgique--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) a annoncé aujourd’hui que la Commission européenne lui avait donné l’autorisation de mise sur le marché de Cytopoint (lokivetmab), le premier traitement par anticorps monoclonal (mAb) autorisé à des fins vétérinaires dans l’Union européenne. Cytopoint est préconisé pour le traitement des signes cliniques, dont les démangeaisons et les signes inflammatoires, associés à la dermatite atopique chez les chiens de tous âges pesant au moins 3 kg. Cytopoint cible et neutralise la cytokine canine interleukin-31 (cIL-31), protéine clé participant au déclenchement des démangeaisons chez les chiens. Administré par injection une fois par mois, Cytopoint permet de soulager rapidement et de manière durable les démangeaisons – signe principal de la dermatite atopique, allergie cutanée affectant les chiens – ainsi que l’inflammation et les lésions causées. Cytopoint permet d’améliorer à long terme la santé et la qualité de vie des chiens souffrant de dermatite atopique, tout en réduisant la frustration et l’inquiétude ressenties par leurs propriétaires. « Personnellement, l’expérience que j’ai eue de Cytopoint a confirmé une efficacité étonnamment rapide, avec une réduction considérable des démangeaisons chez les chiens dès les premières 24 heures, » a déclaré Dr. Emmanuel Bensignor, spécialiste en dermatologie vétérinaire à Paris, qui a participé aux études de terrain menées en Europe. « La dermatite atopique est une maladie très courante chez les chiens, et les propriétaires que je rencontre souhaitent trouver à tout prix une solution rapide, fiable et sûre pour alléger la souffrance de leur chien. Je pense que Cytopoint a le potentiel de répondre aux besoins des propriétaires d’animaux domestiques en raison du côté pratique de son injection mensuelle unique. Avec ce premier traitement par anticorps monoclonal à usage vétérinaire, les dermatologues vétérinaires et les vétérinaires européens pourront désormais accéder à une nouvelle classe thérapeutique. Il s’agit-là d’une innovation très prometteuse qui améliore de manière notable la santé et la qualité de vie des chiens tout en apaisant les inquiétudes de leur famille. » « Nous sommes honorés d’être les premiers à obtenir l’autorisation de la Commission européenne pour la commercialisation d’un traitement par anticorps monoclonal à usage vétérinaire », a souligné Dr. Catherine Knupp, vice-présidente exécutive et présidente de la Recherche et du Développement à Zoetis. « Avec ce traitement pionnier contre la dermatite atopique, nous utilisons une fois encore notre science et nous nous concentrons sur les défis les plus pressants de nos clients pour trouver des solutions dans un domaine où les besoins en matière de santé animale ne sont pas satisfaits. » Selon Dr. Knupp, cette innovation est le fruit d’une analyse scientifique plus approfondie pour comprendre les causes des allergies cutanées chez les chiens au niveau moléculaire et du développement, à partir de cette nouvelle approche, de traitements novateurs, ciblés et efficaces. « Les vétérinaires nous ont fait part de la diversité des besoins des chiens allergiques et de leurs propriétaires. Nous nous félicitons de pouvoir leur offrir deux solutions novatrices avec Cytopoint et notre traitement par comprimé oral, Apoquel. Ces deux médicaments de premier choix constituent pour les vétérinaires deux options efficaces et sûres leur permettant de personnaliser le traitement de la dermatite atopique de leurs patients canins. Je suis vraiment très fière de ces traitements révolutionnaires développés par l’équipe de Zoetis », a souligné Dr. Knupp. Cytopoint est une solution injectable stérile et prête à l’emploi contenant l’anticorps monoclonal mAb lokivetmab. Elle a été spécialement conçue pour cibler et neutraliser la protéine cIL-31, cytokine clé (protéine jouant un rôle important dans la communication entre cellules) qui participe au déclenchement des démangeaisons associées à la dermatite atopique chez les chiens. En imitant l’activité des anticorps naturels, cette solution se fixe de manière sélective aux IL-31 et les neutralise, interrompant ainsi le cycle des démangeaisons dont souffrent les chiens atteints de dermatite atopique. Cytopoint commence à agir dès les huit premières heures et soulage des signes cliniques associés à la dermatite atopique canine pendant un mois, permettant ainsi la cicatrisation des lésions cutanées. Les études cliniques soumises auprès de l’Agence européenne des médicaments ont montré qu’un traitement avec une dose minimum de Cytopoint de 1 mg/kg résultait en la réduction évidente et bénéfique du prurit (démangeaisons) et du niveau de gravité de la maladie selon une évaluation mesurant le degré des lésions cutanées. Ce traitement est sûr pour les chiens de tous âges, même pour ceux souffrant de maladies concomitantes, et peut être utilisé en corrélation avec de nombreux médicaments courants, y compris les vaccins. En outre, en raison de son action précise et spécifique pour cibler et neutraliser la cytokine cIL-31, il a été prouvé que ce traitement n’interférait pas avec la réponse immunitaire, à savoir qu’il ne déclenchait ni d’immunosuppression ni de réponse immunitaire accrue non désirées. Les propriétaires d’animaux domestiques se plaignent le plus souvent des démangeaisons. Celles-ci affectent environ 1 chien sur 6, pour ceux dont les propriétaires sollicitent l’aide d’un vétérinaire.1 Divers facteurs peuvent être à l’origine des démangeaisons, comme des infections, des allergies et des parasites — et environ 15 à 20 % de tous les chiens souffrant de démangeaisons présentent une dermatite atopique.1 Zoetis est la principale entreprise du secteur de la santé animale. Son objectif est d’aider au mieux ses clients et leur entreprise. Forte de plus de 60 ans d’expérience dans le domaine de la santé animale, Zoetis découvre, développe, fabrique et commercialise des vaccins et des médicaments vétérinaires, des produits diagnostiques, des tests génétiques, des équipements bioniques et propose toute une gamme de services. Commercialisant ses produits dans plus de 100 pays, Zoetis répond aux besoins des vétérinaires, des éleveurs de bétail et des personnes qui s’occupent d’animaux domestiques. L’entreprise a généré un chiffre d’affaires annuel de 4,9 milliards de dollars US en 2016 et compte environ 9 000 employés. Pour de plus amples informations, rendez-vous sur le site www.zoetis.com. Déclarations prospectives : Le présent communiqué de presse contient des déclarations prospectives qui reflètent les perspectives actuelles de Zoetis en accord avec ses perspectives ou plans commerciaux, sa performance opérationnelle ou financière future, ses attentes concernant ses produits et autres faits futurs. Les présentes déclarations ne garantissent en rien les résultats ou les actions à venir. Ces déclarations prospectives sont sujettes aux risques et aux incertitudes. Si l’un ou plusieurs de ces risques ou incertitudes se matérialisent, ou si les assomptions sous-sous-jacentes de la direction s’avèrent inexactes, les résultats concrets peuvent différer matériellement de ceux envisagés dans une déclaration prospective. Les déclarations prospectives sont uniquement valides à la date de leur énonciation. Zoetis ne s’engage aucunement à mettre à jour ni à réviser de telles déclarations prospectives, que ce soit suite à de nouvelles informations, d’évènements futurs ou autres. Une liste et une description plus détaillées des risques, des incertitudes et autres points relatifs sont disponible dans notre Rapport annuel sur le Formulaire 10-K de l’année fiscale qui s’est terminée au samedi 31 décembre 2016, y compris dans les sections connexes intitulées « Forward-Looking Statements and Factors That May Affect Future Results » (« Déclarations prospectives et facteurs pouvant affecter les résultats futurs ») et « Item 1A. Risk Factors » (« Article 1A. Facteurs de risques »), consultables dans nos Rapports trimestriels sur le Formulaire 10-Q et dans nos Rapports en cours sur le Formulaire 8-K. Ces dossiers comme ceux à venir sont disponibles en ligne à www.sec.gov, www.zoetis.com, ou sur demande auprès de Zoetis.


Sarasota, FL, April 21, 2017 (GLOBE NEWSWIRE) -- Zion Market Research, the market research group announced the analysis report titled "Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021". The study concludes that the global veterinary vaccine market is expected to grow at a CAGR of 9.3% between 2016 and 2021. The market revenue of $12.10 billion in 2015 is expected to grow up to $20.60 billion by 2021. Vaccination is one of the most used applications of modern biotechnology to prevent chronic bacterial, viral and protozoal diseases. Veterinary vaccines are eco-friendly and used to increase animal welfare by preventing the death of animals, loss of dairy products and monetary loss of owners. Recently highly effective third generation vaccine against rabies virus has been developed with the help of recombinant technology. With the use of the vaccine, we can avoid the problem of antibiotic and drug resistance by the microorganism. Browse through 10 Market Tables and 39 Figures spread through 110 Pages and in-depth TOC on “Global Veterinary Vaccine Market: By Product, Type, Technology, Regions, Poultry, Diseases, Size, Share, Industry Trends, Segments, and Forecast 2015-2021”. Major factors responsible for the growth of veterinary vaccines market include increasing pet ownership, increasing awareness for food security and increasing investment by various government agencies. Increased veterinary research institutions and colleges are also adding value to veterinary vaccines market. However, rising maintenance cost of vaccine storage and prevalence of chronic disease of animals with continuous economic slowdown are hindering the growth of the market. Increasing demand for milk, eggs, meat & animal protein and investment by the government would represent the massive opportunity in future. On the basis of product type, the market of veterinary vaccines is bifurcated into livestock vaccines and companion vaccines. Livestock vaccines account the larger market share of more than 62% and companion vaccines accounts for around 38% share of global veterinary vaccine market. Livestock vaccines segment is classified into poultry, porcine and aquaculture vaccine type. The porcine vaccine is largest sub-segment with more than 30% share of global livestock market and it is expected to remain dominant during the forecast period. Companion vaccine is segmented into equine, canine and feline.  Among these three segments, canine segments are the fastest growing segment with approximately 6% growth rate. Browse the full "Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/veterinary-vaccine-market On the basis of technology type, the veterinary vaccines market is classified into attenuated vaccines, DNA Vaccines, inactivated vaccines, toxoid vaccines, and recombinant vaccines.  With noticeable share, DNA, and attenuated vaccine segments were accounted highest growth for veterinary vaccine market in 2015. The veterinary vaccine market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. As a result of increasing demand for livestock veterinary vaccines, North America and Europe has the strong hold on veterinary vaccine market with more than 68% share. In North America, the U.S. and Canada are two major markets, while the U.S. market is expected to remain dominant with nearly 38% share in forecast period due to increasing pet ownership and growing demand for dairy products. Asia-Pacific is expected to show noticeable growth in forecast period as a result of strong demand from China and India. Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/veterinary-vaccine-market Key operating players for the veterinary vaccines market are Heska Corporation, Zoetis Inc., Ceva Santé Animale Inc., Merck Animal Health, Sanofi (Merial Animal Health), Boehringer Ingelheim GmbH, Eli Lilly and Company (Elanco Animal Health), Virbac, Bayer AG, and Bimeda. Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Loading Zoetis Inc. collaborators
Loading Zoetis Inc. collaborators